

Emmanuel Raffoux

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9060395/publications.pdf>

Version: 2024-02-01

57
papers

1,348
citations

430874

18
h-index

345221

36
g-index

57
all docs

57
docs citations

57
times ranked

2041
citing authors

#	ARTICLE	IF	CITATIONS
1	Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia. <i>Blood</i> , 2015, 125, 3711-3719.	1.4	291
2	Combined Treatment With Arsenic Trioxide and All-Trans-Retinoic Acid in Patients With Relapsed Acute Promyelocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2003, 21, 2326-2334.	1.6	146
3	Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapy. <i>Blood</i> , 2018, 132, 694-706.	1.4	132
4	Nationwide survey on the use of eltrombopag in patients with severe aplastic anemia: a report on behalf of the French Reference Center for Aplastic Anemia. <i>Haematologica</i> , 2018, 103, 212-220.	3.5	62
5	Mutational profile and benefit of gemtuzumab ozogamicin in acute myeloid leukemia. <i>Blood</i> , 2020, 135, 542-546.	1.4	62
6	Real-life experience with CPX-351 and impact on the outcome of high-risk AML patients: a multicentric French cohort. <i>Blood Advances</i> , 2021, 5, 176-184.	5.2	56
7	Management of hyperleukocytosis and impact of leukapheresis among patients with acute myeloid leukemia (AML) on short- and long-term clinical outcomes: a large, retrospective, multicenter, international study. <i>Leukemia</i> , 2020, 34, 3149-3160.	7.2	54
8	Added prognostic value of secondary AML-like gene mutations in ELN intermediate-risk older AML: ALFA-1200 study results. <i>Blood Advances</i> , 2020, 4, 1942-1949.	5.2	49
9	Epidemiology of invasive fungal infections during induction therapy in adults with acute lymphoblastic leukemia: a GRAALL-2005 study. <i>Leukemia and Lymphoma</i> , 2017, 58, 586-593.	1.3	47
10	Evidence of Differentiation in Myeloid Malignancies Associated Neutrophilic Dermatitis: A Fluorescent In Situ Hybridization Study of 14 Patients. <i>Journal of Investigative Dermatology</i> , 2013, 133, 1111-1114.	0.7	37
11	Blinatumomab + ponatinib for relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia in adults. <i>Leukemia and Lymphoma</i> , 2021, 62, 620-629.	1.3	36
12	Nilotinib (Tasigna®) and Low Intensity Chemotherapy for First-Line Treatment of Elderly Patients with BCR-ABL1-Positive Acute Lymphoblastic Leukemia: Final Results of a Prospective Multicenter Trial (EWALL-PH02). <i>Blood</i> , 2018, 132, 31-31.	1.4	36
13	Pre-treatment with oral hydroxyurea prior to intensive chemotherapy improves early survival of patients with high hyperleukocytosis in acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2016, 57, 2281-2288.	1.3	35
14	A Phase II Study of Post-Remission Therapy with Azacitidine (AZA) in Patients with AML Post-MDS and High-Risk MDS: A GFM Group Study. <i>Blood</i> , 2009, 114, 844-844.	1.4	29
15	Vincristine, dexamethasone and epratuzumab for older relapsed/refractory CD22+ B-acute lymphoblastic leukemia patients: a phase II study. <i>Haematologica</i> , 2015, 100, e128-e131.	3.5	26
16	Management and treatment results in patients with acute promyelocytic leukaemia (APL) not enrolled in clinical trials. <i>European Journal of Cancer</i> , 2014, 50, 1159-1168.	2.8	24
17	Next-Generation Sequencing in Myeloid Neoplasm-Associated Sweet's Syndrome Demonstrates Clonal Relation between Malignant Cells and Skin-Infiltrating Neutrophils. <i>Journal of Investigative Dermatology</i> , 2020, 140, 1873-1876.e5.	0.7	23
18	Adult T-cell acute lymphoblastic leukemias with IL7R pathway mutations are slow-responders who do not benefit from allogeneic stem-cell transplantation. <i>Leukemia</i> , 2020, 34, 1730-1740.	7.2	21

#	ARTICLE	IF	CITATIONS
19	Combination of vorinostat and low dose cytarabine for patients with azacitidine-refractory/relapsed high risk myelodysplastic syndromes. <i>Leukemia Research</i> , 2014, 38, 29-33.	0.8	16
20	Impact of additional genetic alterations on the outcome of patients with NPM1-mutated cytogenetically normal acute myeloid leukemia. <i>Haematologica</i> , 2015, 100, e196-e199.	3.5	16
21	Interferon-Alpha (IFN) Therapy Discontinuation Is Feasible in Myeloproliferative Neoplasm (MPN) Patients with Complete Hematological Remission. <i>Blood</i> , 2020, 136, 35-36.	1.4	16
22	Evolving characteristics and outcome of secondary acute promyelocytic leukemia (<sc>APL</sc>): A prospective analysis by the <sc>F</sc>renchâ€<sc>B</sc>elgianâ€<sc>S</sc>wiss <sc>APL</sc> group. <i>Cancer</i> , 2015, 121, 2393-2399.	4.1	15
23	Patterns of care and clinical outcomes of patients with newly diagnosed acute myeloid leukemia presenting with hyperleukocytosis who do not receive intensive chemotherapy. <i>Leukemia and Lymphoma</i> , 2020, 61, 1220-1225.	1.3	15
24	Early detection of <i>WT1</i> measurable residual disease identifies high-risk patients, independent of transplantation in AML. <i>Blood Advances</i> , 2021, 5, 5258-5268.	5.2	12
25	Dose-Intensity Impacts On Survival of Adolescents and Young Adults with Acute Lymphoblastic Leukemia Treated in Adult Departments by a Pediatric Protocol (FRALLE 2000BT). <i>Blood</i> , 2012, 120, 3561-3561.	1.4	10
26	Low-Dose Clofarabine Has Significant Activity in High-Risk Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia Post-MDS (sAML) After Azacitidine (AZA) Failure: Interim Results of the GFM Clo08 Dose Escalating Phase I/II Study (NCT0106325). <i>Blood</i> , 2011, 118, 609-609.	1.4	8
27	Identification Of Patients (pts) With Chronic Myeloid Leukemia (CML) At High Risk Of Artery Occlusive Events (AOE) During Treatment With The 2nd Generation Tyrosine Kinase Inhibitor (TKI) Nilotinib, Using Risk Stratification For Cardiovascular Diseases (CVD). <i>Blood</i> , 2013, 122, 2726-2726.	1.4	8
28	Minimal residual disease monitoring in acute myeloid leukemia with non-A/B/D-NPM1 mutations by digital polymerase chain reaction: feasibility and clinical use. <i>Haematologica</i> , 2021, 106, 1767-1769.	3.5	8
29	Granulomonocytic progenitors are key target cells of azacytidine in higher risk myelodysplastic syndromes and acute myeloid leukemia. <i>Leukemia</i> , 2018, 32, 1856-1860.	7.2	7
30	Hyper-CVAD + epratuzumab as a salvage regimen for younger patients with relapsed/refractory CD22-positive precursor B-cell acute lymphocytic leukemia. <i>Haematologica</i> , 2017, 102, e184-e186.	3.5	6
31	Outcomes Following Hematopoietic Stem Cell Transplantation in Patients Treated with Chemotherapy with or without Gemtuzumab Ozogamicin for Acute Myeloid Leukemia. <i>Blood</i> , 2018, 132, 28-28.	1.4	5
32	Gut Aspergillus Infections in Leukemia and Stem Cell Transplant Patients: A Rare and Unrecognized Disease.. <i>Blood</i> , 2009, 114, 2220-2220.	1.4	5
33	Liposomal cytarabine in prophylaxis or curative treatment of central nervous system involvement in Burkitt leukemia/lymphoma. <i>Annals of Hematology</i> , 2015, 94, 1859-1863.	1.8	4
34	Characteristics, Treatment Patterns and Outcomes Among Newly Diagnosed Patients (pts) with Acute Myeloid Leukemia (AML) Who Present with Hyperleukocytosis: Findings from a Large International Patient Cohort. <i>Blood</i> , 2018, 132, 4040-4040.	1.4	4
35	<i>SF3B1</i> mutations in the Driver Clone Increase the Risk of Evolution to Myelofibrosis in Patients with Myeloproliferative Neoplasms (MPN). <i>Blood</i> , 2020, 136, 1-1.	1.4	4
36	Hepatosplenic Candidiasis in Patients With Hematological Malignancies: A 13-Year Retrospective Cohort Study. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofac088.	0.9	4

#	ARTICLE	IF	CITATIONS
37	Myeloproliferative Neoplasms (MPN) Clonal Evolution Landscape and Its Impact on Patients' Prognosis. <i>Blood</i> , 2021, 138, 317-317.	1.4	3
38	Life expectancy and burden of late complications after reduced intensity conditioning allogeneic transplantation. <i>Bone Marrow Transplantation</i> , 2022, 57, 1365-1372.	2.4	3
39	Oncogenic Predictors of Outcome in Older AML Patients Treated Intensively. Analysis of the ALFA-1200 Trial. <i>Blood</i> , 2018, 132, 993-993.	1.4	2
40	A Phase I-II Study Of The Efficacy and Safety Of Lenalidomide (LEN) Combined To Azacitidine (AZA) In Higher Risk MDS and AML With Del 5q "A Study By The Groupe Francophone Des Myelodysplasies (GFM). <i>Blood</i> , 2013, 122, 2750-2750.	1.4	2
41	NFE2 Mutations Impact AML Transformation and Overall Survival in Patients with Myeloproliferative Neoplasms (MPN). <i>Blood</i> , 2020, 136, 36-36.	1.4	2
42	Molecular Characterization of Clinical Response and Relapse in Patients with <i>IDH1</i> -Mutant Newly Diagnosed Acute Myeloid Leukemia Treated with Ivosidenib and Azacitidine. <i>Blood</i> , 2020, 136, 49-51.	1.4	1
43	Intensive Consolidation with Clofarabine and Intermediate-Dose Cytarabine (CLARA) in Patients with High-Risk AML in First CR: The ALFA-0702 Pilot Study.. <i>Blood</i> , 2008, 112, 1934-1934.	1.4	1
44	Final Report of GFM-VOR2007 Study: a Phase I/II Study of Vorinostat and Low Dose Cytarabine (LDAC) for MDS Patients with Azacitidine (AZA) Failure. <i>Blood</i> , 2012, 120, 3825-3825.	1.4	1
45	Impact of Leukapheresis and Time to Chemotherapy on Outcomes of Newly Diagnosed Patients (pts) with Acute Myeloid Leukemia (AML) Presenting with Hyperleukocytosis: An Analysis from a Large International Patient Cohort. <i>Blood</i> , 2018, 132, 1428-1428.	1.4	1
46	Outcomes of Patients with Newly-Diagnosed Acute Myeloid Leukemia and Hyperleukocytosis Who Did Not Undergo Intensive Chemotherapy: Results from a Large International Database. <i>Blood</i> , 2018, 132, 3999-3999.	1.4	1
47	Retrospective Analysis of the Outcomes of Patients with Relapsed/Refractory Acute Myeloid Leukemia Included in a Patient Named Program of Gemtuzumab Ozogamicin. <i>Blood</i> , 2021, 138, 876-876.	1.4	1
48	Genomic Landscape and Clinical Features of Myeloproliferative Neoplasm (MPN) Patients with Auto-Immune and Inflammatory Diseases (AID). <i>Blood</i> , 2021, 138, 1496-1496.	1.4	1
49	Characteristics and mid-term follow-up of COVID-19 patients with hematological diseases: a retrospective study from a French tertiary care hospital. <i>Blood Cancer Journal</i> , 2021, 11, 129.	6.2	0
50	Fatigue and Daily Life in Patients with Essential Thrombocythemia: Comparisons Between the USA and France in 447 Patients.. <i>Blood</i> , 2009, 114, 2904-2904.	1.4	0
51	Therapy Related APL (tAPL). Prospective Analysis of Etiological Factors In Recent Cases, and Comparison with De Novo Cases. <i>Blood</i> , 2010, 116, 2171-2171.	1.4	0
52	Early Admission to the Intensive Care Unit In High Risk Acute Myeloid Leukemia Patients. <i>Blood</i> , 2010, 116, 4364-4364.	1.4	0
53	Oral Hydroxyurea Before Intensive Chemotherapy For Hyperleucocytic Acute Myeloid Leukemia Patients. <i>Blood</i> , 2013, 122, 2657-2657.	1.4	0
54	Epidemiology Of Invasive Aspergillosis (IA) During Induction Therapy In Adults With Acute Lymphoblastic Leukemia (ALL): A Graall-2005 Study. <i>Blood</i> , 2013, 122, 1394-1394.	1.4	0

#	ARTICLE	IF	CITATIONS
55	Arsenic Trioxide (ATO) Or ATRA For Consolidation Treatment Of Standard Risk Non Elderly Newly Diagnosed APLâ€™ Second Interim Analysis Of a Randomized Trial (APL 2006) By The French Belgian Swiss APL Group. Blood, 2013, 122, 495-495.	1.4	0
56	Intra-Tumor Heterogeneity in Acute Myeloid Leukemia (AML): Results from a Real Life Cohort. Blood, 2018, 132, 1537-1537.	1.4	0
57	Myeloid Blast Crisis of Philadelphia Positive Chronic Myeloid Leukemia and Philadelphia Positive Acute Myeloid Leukemia Treated at the AP-HP in Paris: A Retrospective Analysis. Blood, 2020, 136, 35-36.	1.4	0